APA (7th ed.) Citation

J, G., L, G., N, L., A, S., A, R., JF, C., . . . JF, R. (2025). Open-label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced non-resectable granulosa cell ovarian tumors: The Greko II study (GETHI2013-01). Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 27(7), 3223. https://doi.org/10.1007/s12094-024-03827-4

Chicago Style (17th ed.) Citation

J, Garcia-Donas, et al. "Open-label Phase II Clinical Trial of Orteronel (TAK-700) in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors: The Greko II Study (GETHI2013-01)." Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 27, no. 7 (2025): 3223. https://doi.org/10.1007/s12094-024-03827-4.

MLA (9th ed.) Citation

J, Garcia-Donas, et al. "Open-label Phase II Clinical Trial of Orteronel (TAK-700) in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors: The Greko II Study (GETHI2013-01)." Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, vol. 27, no. 7, 2025, p. 3223, https://doi.org/10.1007/s12094-024-03827-4.